

Press release from Biora AB (publ), June 12, 2003

No 11/03

FOR IMMEDIATE

R E L E A S E

Compulsory Acquisition of Biora AB Ordinary Shares.

Straumann AG Holdings ("Straumann") has announced that it has acquired approximately 91 percent of the Ordinary Shares of Biora AB pursuant to its public offer. Straumann has called for the compulsory acquisition of the remaining outstanding Biora Ordinary Shares. Accordingly, the Biora Board has decided to refer the compulsory acquisition matter to an arbitration board. The Board of Biora has also decided to sub mit an application for de-listing Biora's Ordinary Shares from the "O-list" of the Stockholm Stock Exchange ("SSE"). Information regarding the last trading day for Biora's Ordinary Shares on the SSE will be announced at a later date.

Malmö, June 12th 2003

The Board of Biora AB Per Wahlström, Chairman of the Board

Biora develops manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain® Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.

This press release may contain certain forward-looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.

For further information, please contact:

- Svante Lundell, CFO and Investor Relations, Biora + 46-70 532 30 65
- Per Wahlström, Chairman of the Board, Biora, tel: +46-70-591 39 29
- h t t p : // w w w . b i o r a . c o m